摘要
目的观察促性腺激素释放激素类似物(GnRHa)治疗中枢性性早熟(CPP)在改善成年身高方面的疗效。方法比较30例经GnRHa治疗并已达接近成年身高(FAH)的CPP女孩治疗开始和结束时的预测成年身高(PAH1和PAH2)、遗传靶身高(THt)和FAH,判断GnRHa的疗效,并分析其影响因素。结果PAH2[(155.2±5.7)cm]显著高于PAH1[(150.7±5.4)cm](P<0.01),PAH2、THt [(155.5±4.0)cm]和FAH[(155.7±4.9)cm]的差异无统计学意义;治疗开始的年龄和按THt的PAH标准差分值以及GnRHa疗程是影响GnRHa疗效的3个因素。结论GnRHa能有效改善CPP女孩的成年身高,成年身高的改善主要决定于治疗开始时的年龄和预测成年身高相对于遗传靶身高的损失以及GnRHa的疗程。
Objective To investigate the long-term outcome in the girls with central precocious puberty (CPP) treated by gonadotropin-releasing hormone analogue (GnRHa). Methods Thirty girls with idiopathic CPP treated with GnRHa for (23.0±7.6)months achieved their near final heights after (3.2±0.8)years follow-up. Comparisons were made among their final adult height (FAH), target height (THt), predicted adult height(PAH)at the onset and the end of GnRHa treatment (PAH 1 and PAH 2) . Factors affecting the height gain were also analysed. Results PAH increased after the GnRHa treatment [ PAH 2(155.2±5.7)cm vs PAH 1 (150.7±5.4)cm,P<0.01]. There was no significant difference among PAH 2, THt [(155.5±4.0)cm] and FAH [(155.7±4.9)cm]. Age (CA 1), predicted adult height SDS for target height (PAH 1SDS THt) at the onset of GnRHa treatment, and duration of GnRHa treatment were the 3 variables being able to influence independently the effective height gain from the start of treatment to the achievement of adult height. The better height gain by GnRHa treatment is relatedto the younger age, the shorter PAHcompared to the target height at the initial treatment and the longer duration of GnRHa therapy. Conclusions GnRHa improves the final height of CPP girls, with the effect being influenced by the age, the initial deficit in height potential at the onset of treatment and the duration of GnRHa application.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2005年第3期240-243,共4页
Chinese Journal of Endocrinology and Metabolism
